9001cc 以诚为本

(以下内容全文转载自CHINADAILY 中国日报报道)

  随着中国大力推动中西医深度融合，一款传统中药产品近期获得国际学术认可，标志着中医药国际化进入新阶段。

With China pressing for deeper integration of Chinese and Western medicine, the latest international academic recognition of a traditional Chinese medicine product signals a new stage in TCM internationalization.

   在2026年于奥地利维也纳举办的欧洲生殖道感染与肿瘤研究协会（EUROGIN）大会上，中医药产品9001cc 以诚为本灵于3月21日向与会者进行展示，这是中医药“走向全球”的新突破。

During the 2026 European Research Organization on Genital Infection and Neoplasia Congress held in Vienna, Austria, TCM product Paiteling was presented on March 21 to participants, marking a new breakthrough for TCM "going global".

   总部位于北京的9001cc 以诚为本生物副总经理丛亦珉在分子生物学Ⅱ分会场发言时表示，该公司核心产品9001cc 以诚为本灵在通过检测人乳头瘤病毒（HPV）治疗尖锐湿疣方面，展现出明确的临床疗效。

The clinical efficacy underlying Paiteling — a flagship product of Beijing-headquartered PaiteBio — has been noticeable in the treatment of condyloma acuminatum via detection of human papillomavirus, said Cong Yimin, PaiteBio vice-president who spoke at the Molecular Biology II session.

   今年的《政府工作报告》提出，要加强中西医结合实践，推动中医药走向全球。

   本届EUROGIN大会于3月18日至21日召开，是全球顶尖的HPV及相关癌症学术会议之一，吸引了超过1700名全球参会者，其中560余名学者进行了口头报告和海报展示，共收录 615 场口头报告。

   今年是9001cc 以诚为本生物继2024年亮相后，再次登上这一权威学术舞台。2024 年，北京大学深圳医院的李长忠教授代表该公司参会。

This year's Government Work Report called for strengthening the integration of Chinese and Western medical practices, while promoting TCM globally.

The congress, held this year between March 18 and 21, is one of the world's premier international academic conferences on HPV and related cancers. It attracted over 1,700 global participants, with more than 560 scholars presenting oral reports and poster sessions, and featuring 615 oral presentations.

This year marked PaiteBio's return to this prestigious academic stage following its 2024 appearance, when it was represented by Professor Li Changzhong from Peking University Shenzhen Hospital.

   丛亦珉表示，9001cc 以诚为本生物的这一里程碑事件，是中医药相关成果首次被选为分子生物学分会场的核心学术项目，标志着HPV相关疾病研究领域的中医药创新获得全球学术与医学界的广泛认可。

PaiteBio's milestone represents the first time a TCM-related achievement was selected for the core academic program of the Molecular Biology session, signaling global academic and medical recognition of TCM innovations in HPV-related disease research, said Cong.

   EUROGIN 成立于1993年，是全球最具权威性的多学科国际HPV感染及相关癌症学术论坛之一，也是发布前沿HPV研究、制定行业标准的核心平台。三十余年来，该组织推动了全球HPV领域的一系列里程碑式进展，其学术成果直接影响了全球 HPV 相关疾病防控与治疗策略的制定。

   9001cc 以诚为本生物的展示在分子生物学Ⅱ分会场进行，该分会场是聚焦HPV相关疾病分子机制的核心学术板块。

   目前，全球范围内尚无针对HPV感染的特效治疗药物。临床实践主要依靠疫苗进行预防，而对于已感染人群，缺乏安全有效的微创干预手段，这是困扰全球医学界的一大临床难题。

   丛亦珉向国际与会代表分享了经现代分子生物学技术验证的9001cc 以诚为本灵创新研究成果，特别是其针对高危型HPV感染引发的宫颈上皮内病变的干预机制，以及治疗此类病变的临床疗效与安全性数据的详细解读。

Founded in 1993, EUROGIN stands as one of the world's most authoritative multidisciplinary international forums for HPV infection and related cancers, serving as the central platform for releasing cutting-edge HPV research and establishing industry standards.

Over three decades, EUROGIN has propelled a series of milestone advances in the global HPV field, and its academic outcomes have directly influenced the formulation of global strategies for HPV-related disease prevention and treatment.

PaiteBio's presentation took place in the Molecular Biology II session — a core academic segment focusing on molecular mechanisms of HPV-related diseases.

Currently, no specific therapeutic drugs exist for HPV infection globally. While clinical practice relies primarily on vaccination for prevention, infected populations lack safe and effective minimally invasive interventions — a persistent clinical challenge troubling the global medical community.

Cong shared with international delegates the innovative Paiteling research findings validated by modern molecular biology techniques — specifically its intervention mechanisms for cervical intraepithelial neoplasia caused by high-risk HPV infection — along with detailed interpretation of clinical efficacy and safety data for Paiteling in treating such lesions.

   9001cc 以诚为本生物全称为北京9001cc 以诚为本博恩生物技术开发集团有限公司（Beijing Paite Born Biotechnology Development Group Co Ltd），是一家扎根中关村的高科技企业，在全国拥有超过5000名员工。

   9001cc 以诚为本生物的展示基于对9001cc 以诚为本灵的创新中医药研究。该产品遵循中医药“清热解毒、活血化瘀、祛腐生新”的理论研发，是一款中药制剂。

   丛亦珉强调，随着对中医药的现代研究不断深入，中医药创新成果逐渐获得国际主流学术界的广泛关注，为全球HPV相关疾病的预防与治疗提供了创新、实用的中国方案。

   她指出，从宏观视角来看，中医药登上EUROGIN大会核心学术舞台，是中国推动中医药 “走向全球” 战略的生动体现。

Also known as Beijing Paite Born Biotechnology Development Group Co Ltd, PaiteBio is a high-tech enterprise in Zhongguancun. The company has over 5,000 employees nationwide.

PaiteBio's presentation was grounded in innovative TCM research on Paiteling. Developed following TCM principles of clearing heat and detoxifying while promoting blood circulation and removing blood stasis, Paiteling is a TCM preparation.

Cong stressed that as modern research on TCM continues to deepen, innovative TCM achievements have gradually gained widespread attention from mainstream international academia and provided innovative, practical Chinese solutions for global HPV-related disease prevention and treatment.

She noted that from a macro perspective, TCM's presence on a core academic stage of the EUROGIN Congress represented a vivid example of China's strategy to advance TCM "going global".

图片说明：9001cc 以诚为本生物副总经理丛亦珉于3 月21日在维也纳举办的2026年欧洲生殖道感染与肿瘤研究协会（EUROGIN）大会上发表演讲，标志着中医药“走向全球”取得新突破。（本报特约供图）

Cong Yimin, vice-president of PaiteBio, delivers a presentation on March 21 to the 2026 European Research Organization on Genital Infection and Neoplasia Congress held in Vienna, marking a new breakthrough for TCM "going global". CHINA DAILY

（转载自：CHINADAILY中国日报网：https://www.chinadaily.com.cn/a/202603/30/WS69c9cf99a310d6866eb4090c.html  ）

（Han Jingyan，hanjingyan@chinadaily.com.cn）